Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2020-05-04 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 30/04/2020. The document includes confirmations by a director regarding compliance with listing rules and legal requirements. There are no financial statements, earnings data, or management discussion of financial results. The content focuses exclusively on share capital changes and related confirmations, which aligns with announcements about share capital changes rather than full financial reports or earnings releases. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is substantial (13,747 characters), indicating it is the report itself, not just an announcement of a report publication or a certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2020-05-04 English
VOLUNTARY ANNOUNCEMENT - "ORNITHINE ASPARTATE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a short announcement (2326 characters) from CSPC Pharmaceutical Group Limited regarding the approval of a drug registration by the National Medical Products Administration of China. It is titled as a "Voluntary Announcement" and contains no financial data, no detailed financial statements, or comprehensive report content. It is not an earnings release, annual report, or any detailed financial or management report. The content is an update on a product approval, which is a regulatory or corporate announcement rather than a financial report. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory or corporate announcements that do not fit other specific categories.
2020-05-04 English
PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 15 JUNE 2020 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for the Annual General Meeting (AGM) of CSPC Pharmaceutical Group Limited, scheduled for June 15, 2020. It includes instructions for shareholders to appoint proxies and vote on various resolutions such as receiving the audited financial statements, re-electing directors, approving dividends, and authorizing share buy-back and issuance mandates. The content is procedural and related to voting at the AGM rather than the actual AGM materials or presentations. Therefore, this document is best classified as Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2020-04-27 English
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF 2019 ANNUAL REPORT AND THE CIRCULAR DATED 28 APRIL 2020
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated 28 April 2020 from CSPC Pharmaceutical Group Limited informing non-registered shareholders about the publication of the 2019 annual report and a circular. It provides instructions on how to request printed copies of these documents and future corporate communications. The letter directs recipients to the company's website and the Hong Kong Stock Exchange website to access the documents. There is no actual financial data or report content included in this document; it is purely an announcement of the availability of the annual report and circular. The document length is 6968 characters, which is relatively short and consistent with a notification letter rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of report publication, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2020-04-27 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice for an Annual General Meeting (AGM) of CSPC Pharmaceutical Group Limited. It includes details about the meeting date, agenda items such as receiving audited financial statements, dividend declaration, re-election of directors, appointment of auditors, and various shareholder resolutions including share buyback and share issuance mandates. The document is a formal announcement inviting shareholders to attend the AGM and vote on these matters. It does not contain the actual financial statements or detailed financial performance data, but rather the notice of the meeting and the business to be conducted. Therefore, it fits the category of AGM Information (AGM-R).
2020-04-27 English
PROPOSALS FOR ISSUE OF BONUS SHARES, GENERAL MANDATES TO BUY-BACK SHARES AND TO ISSUE SHARES AND MANDATE TO GRANT OPTIONS, RE-ELECTION OF THE RETIRING DIRECTORS, AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a detailed circular from CSPC Pharmaceutical Group Limited dated April 28, 2020, addressing multiple corporate proposals including the issue of bonus shares, general mandates to buy back and issue shares, mandate to grant options, re-election of retiring directors, and notice of the Annual General Meeting (AGM). It includes a notice of the AGM, proxy form instructions, precautionary measures for the AGM, expected timetable, definitions, and a letter from the board explaining the proposals. The document is comprehensive and intended for shareholders to inform them and seek approval at the AGM. This type of document is a circular related to the AGM, containing materials and information to be considered at the meeting, which fits the definition of AGM Information (AGM-R). It is not an announcement of voting results, nor a financial report or earnings release. The length and content confirm it is the meeting circular itself, not just an announcement or proxy solicitation alone. Therefore, the correct classification is AGM Information (AGM-R).
2020-04-27 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.